|
US2020390736A1
|
|
Use of an RXR agonist in treating HER2+ cancers
|
|
WO2020251556A1
|
|
Use of an rxr agonist in treating her2+ cancers
|
|
AU2018367653A1
|
|
Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids
|
|
AU2018335393A1
|
|
Treatment of disease with esters of selective RXR agonists
|
|
WO2019046591A1
|
|
Rar selective agonists in combination with immune modulators for cancer immunotherapy
|
|
KR20200029544A
|
|
Immunomodulatory retinoid and rexinoid compounds combined with immunomodulators for cancer immunotherapy
|
|
EP3468600A1
|
|
Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
|
|
US2018333380A1
|
|
Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
|
|
EP3368160A1
|
|
Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists
|
|
CN109069645A
|
|
With the treatment of the combined muscle disease of rxr agonist and thyroid hormone
|
|
CN108289958A
|
|
Use the combined therapy nerve problems of rxr agonist and thyroid hormone
|
|
AU2016396658A1
|
|
Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
|
|
US2019365681A1
|
|
Treatment of cancer with combinations of rxr agonists and thyroid hormones
|
|
US2015038585A1
|
|
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
|
WO2014110165A1
|
|
Treatment of graft-versus-host disease disorders using rar antagonists
|
|
EP2685972A2
|
|
Inflammation and autoimmune disorder treatment using rar alpha selective agonists
|
|
CN101472572A
|
|
Use of a RAR antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects
|
